In the latest Profits Unlimited issue Paul Mampilly explains to his readers why he thinks precision medicine is a great area to invest money in. He let his 90,000 readers know that there is a revolution in precision medicine and it will soon take up a bigger slice of the healthcare industry. Some of the language he used to describe the trends in this industry included calling it among the biggest medical breakthrough in history. In particular he wrote about one firm located in the Midwest which he told his subscribers they really should be investing their money in because it is going to explode in value. Read this article at Daily Forex Report.

Paul Mampilly has been in a number of positions in the financial sector. He graduated from Fordham University in 1996 which is where he earned his MBA. His first job in the industry occurred a number of years prior to that when he was an assistant portfolio manager. In 2006 he became a hedge fund manager. This occurred at Kinetics Asset Management. During his time with this company their assets under management increased to $25 billion and he averaged 26% returns.

He writes about his views on various companies in Profits Unlimited which has a new issue each month. He also writes about various industries and the opportunities in them in another newsletter, Extreme Fortunes. Additionally, Paul Mampilly operates a research service that he named “True Momentum“.

Increasingly doctors today can look at a patient’s DNA and determine what medicines they will most positively react to based on their genetic makeup. Doctors are even beginning to determine if a person will develop a disease and then start a customized regimen to keep them healthy. This includes many age related diseases such as heart disease, Parkinson’s disease, diabetes, and arthritis. The company Paul Mampilly told his subscribers about is presently worth $1.5 billion and is poised to be worth much more in the not so distant future.

The company Paul Mampilly is talking about is called Myriad Genetics. They sell a kit consumers make use of and then send back to this company. Myriad Genetics then diagnoses the kit and determines what their odds are of developing cancer. They are starting to move out to other diseases as well although most of their money is presently made from screening for cancers such as colon, breast, and prostate cancers among others. Check: https://banyanhill.com/expert/paul-mampilly/

 


Comments are Closed on this Post